Cargando…

Novel Coagulation Factor VIII Gene Therapy in a Mouse Model of Hemophilia A by Lipid-Coated Fe(3)O(4) Nanoparticles

Hemophilia A is a bleeding disease caused by loss of coagulation factor VIII (FVIII) function. Although prophylactic FVIII infusion prevents abnormal bleeding, disability and joint damage in hemophilia patients are common. The cost of treatment is among the highest for a single disease, and the adve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kao, Yung-Tsung, Chen, Yen-Ting, Fan, Hueng-Chuen, Tsai, Tung-Chou, Cheng, Shin-Nan, Lai, Ping-Shan, Chen, Jen-Kun, Chen, Chuan-Mu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464966/ https://www.ncbi.nlm.nih.gov/pubmed/34572302 http://dx.doi.org/10.3390/biomedicines9091116

Ejemplares similares

Therapeutic Effects of Kefir Peptides on Hemophilia-Induced Osteoporosis in Mice With Deficient Coagulation Factor VIII
por: Yen, Chih-Ching, et al.
Publicado: (2022)

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment
por: Kao, Yung-Tsung, et al.
Publicado: (2023)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Oral immunotherapy with the ingestion of house dust mite extract in a murine model of allergic asthma
por: Wang, Yao-Tung, et al.
Publicado: (2018)

Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII
por: Chen, Hainan, et al.
Publicado: (2019)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes
por: Dalm, Daniela, et al.
Publicado: (2015)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A
por: Gong, Jie, et al.
Publicado: (2021)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, F., et al.
Publicado: (2022)

Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice
por: Sarafanov, Andrey G.
Publicado: (2023)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
por: Sun, Jing, et al.
Publicado: (2021)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
por: Owaidah, Tarek M., et al.
Publicado: (2020)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII
por: Sayyadipour, Fatemeh, et al.
Publicado: (2020)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, Feng, et al.
Publicado: (2023)

Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia
por: Lee, Soo Ok, et al.
Publicado: (2016)

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2018)

Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A
por: Csencsits-Smith, Keri, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3k2mapi9rp8g0erkkfmapno9cf